We sought to define optimal conditions for retroviral-mediated transduction of long-lived human hematopoietic progenitors from bone marrow and peripheral blood. CD34+ cells were transduced by the LN and G2 retroviral vectors in the presence or absence of stromal support and with or without cytokine addition. After transduction, a portion of the cells was plated in methylcellulose colony-forming assay, with or without G418, to assess the extent of gene transfer into committed progenitors. The remaining cells from each experiment were transplanted into immunodeficient mice to allow analysis of transduction of long-lived progenitors. Human colony-forming cells contained within the murine bone marrow were analyzed after engraftment periods of 2 to 11 months. Cells were plated in a humanspecific colony-forming assay with and without G418 to assess the extent of transduction of primitive progenitors. Individual human colonies were also analyzed by polymerase chain reaction for the presence of provirus. Bone marrow progenitors were efficiently transduced only when stroma was present, whereas mobilized peripheral blood progeni-S CLINICAL TRIALS have begun using retroviral-mediated gene transfer into human hematopoietic progenitors, a number of specific methodologic issues remain unresolved. Our group and others have shown that the extent of gene transfer into clonogenic progenitor cells from human bone marrow is increased by addition of recombinant cytokines (such as interleukin-3 [IL-31, IL-6, and stem cell factor [SCF]) to the hematopoietic cells before and/or during gene tran~fer.'.~ Moore et a14 have shown that the presence of an underlayer of irradiated marrow stromal cells during transduction of bone marrow progenitors increases gene transfer and eliminates the need to add recombinant cytokines. Other investigators have reported relatively efficient gene transfer into granulocyte colony-stimulating factor (G-CSF)-or granulocyte-macrophage CSF (GM-CSF)-mobilized peripheral blood cell progenitors in the absence of No study reported to date has directly compared various transduction conditions for bone marrow versus mobilized peripheral blood progenitor cells.
S CLINICAL TRIALS have begun using retroviral-mediated gene transfer into human hematopoietic progenitors, a number of specific methodologic issues remain unresolved. Our group and others have shown that the extent of gene transfer into clonogenic progenitor cells from human bone marrow is increased by addition of recombinant cytokines (such as interleukin-3 [IL-31, IL-6, and stem cell factor [SCF] ) to the hematopoietic cells before and/or during gene tran~fer.'.~ Moore et a14 have shown that the presence of an underlayer of irradiated marrow stromal cells during transduction of bone marrow progenitors increases gene transfer and eliminates the need to add recombinant cytokines. Other investigators have reported relatively efficient gene transfer into granulocyte colony-stimulating factor (G-CSF)-or granulocyte-macrophage CSF (GM-CSF)-mobilized peripheral blood cell progenitors in the absence of No study reported to date has directly compared various transduction conditions for bone marrow versus mobilized peripheral blood progenitor cells.
Each of the previous studies examined the directly clonogenic progenitor cells or progenitors present after 5 weeks of long-term bone marrow culture. Gene transfer studies in large animal models have shown that results measured in these relatively mature progenitor cells do not predict success at transducing long-lived stem cells measured after transplantation into irradiated recipient^.^.^ We have recently described a model that allows human marrow to be maintained in vivo in immune deficient mice for at least 9 months." The human progenitor cells present in the murine marrow after extended periods of engraftment can be specifically grown in culture and assayed for the presence of the marker gene.
We have now used this human xenograft system to directly compare the requirements for efficient retroviral-mediated transduction of long-lived human progenitor cells from bone marrow and G-CSF-mobilized peripheral blood. We found that transduction in the presence of stroma was the most effective method for both cell types. Bone marrow tors were effectively transduced in the presence of either stroma or cytokines. Inclusion of the cytokines interleukin-3, interleukin-6, and stem cell factor did not further augment the extent of gene transfer in the presence of a stromal support layer. Additionally, human CD34' Progenitors from bone marrow or mobilized peripheral blood that had been transduced for 3 days in the absence of stroma failed to produce sustained, long-term engraftment of bnxmice. Mice transplanted with the same pools of human progenitors that had been transduced in the presence of stroma for 3 days had significant levels of human cell engraftment at the same timepoints, 7 to 11 months after transplantation. Our data show loss of long-lived human progenitors during 3-day in vitro transduction periods in the absence of stromal suppo~. Therefore, the presence of bone marrow stroma has dual benefits in that it increases gene transfer efficiency and is essential for survival of long-lived human hematopoietic progenitors.
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was efficiently transduced only when stroma was present, whereas G-CSF-mobilized peripheral blood was effectively transduced in the presence of either stroma or cytokines. In all cases, the presence of a stromal underlayer during exposure to the retroviral supernatant obviated the need for exogenous recombinant cytokines. In addition, the presence of a stromal support layer during the 3-day in vitro transduction period preserved the viability of the primitive human cells that then survived for 7 to 11 months in bnx mice. Human progenitors transduced for 3 days in the presence of the cytokines, but without a stromal support layer, failed to engraft bnx mice to significant levels beyond 5 months. Our data suggest that loss or damage of long-lived, primitive human hematopoietic progenitors occurs during the 72-hour in vitro period without stromal support. ." I' The G2 and L-IL-3-SN vectors, which carry normal human glucocerebrosidase (GC) and 11,-3 cDNA, respectively, were constructed and packaged as described."'.13 Vector-producing cell lines were grown in Dulbecco's modified Eagle's medium with high glucose (Irvine Scientific, Santa Ana, CA) and 10% prescreened fetal calf serum (FCS; Gemini Bioproducts, Calabasas, CA). Supernatant was harvested 24 hours after a media change on confluent monolayers, and aliquots of retroviral supernatant were stored at -70°C.
Humun bone murrow. Normal human bone marrow cells were obtained from screens used to filter marrow during harvest of allogeneic donors. Use of these samples was approved by the Committee on Clinical Investigations at Childrens Hospital Los Angeles. Peripheral blood cells mobilized with G-CSF were excess from clinical trials performed at UCLA and were generously provided by Dr Michael Lill (UCLA School of Medicine). Light-density mononuclear cells were obtained by centrifugation on ficoll-percoll gradients (Sigma CO, St Louis, MO) and plated at a density of 5 X IO5 cellslmL in Iscove's modified Dulbecco's medium (IMDM; GIBCO, Grand Island, NY) with 20% FCS. Cells were incubated for 4 to 8 hours at 37°C with 5% CO, to allow adherence of CD34' endothelial cells before isolation of CD34' hematopoietic progenitors.
Stromal cells. Spicules from unseparated bone marrow were collected by gravity sedimentation and plated in stromal medium, which is IMDM with 15% FCS, 15% horse serum (Gemini Bioproducts), 10-' mol/L 2-mercaptoethanol (Sigma), 1 O-' mol/L hydrocortisone (Sigma), 50 U/mL penicillin G, 50 p g h L streptomycin sulfate, and 2 mmol/L L-glutamine (Irvine Scientific). Subconfluent layers of primary stromal cells were split by trypsinization (trypsin-EDTA; Irvine Scientific). Stroma was not used as a supporting layer for transduction until passage no. 4. At this point, most hematopoietic cells had been eradicated, except for mature macrophages, which comprised less than 1% of the culture, as shown by fuorescenceactivated cell sorter (FACS) analysis and immunohistochemical staining for the panleukocyte antigen CD45 using the monoclonal antibody HLE-I (Becton Dickinson
[BD], San Jose, CA) as described." Stromal cells were irradiated (20 Gy) and plated at 5 X 10' cells per T-25 vent-cap flask (Costar, Cambridge, MA) in IMDM/ 20% FCS the day before use.
Transduction of CD34' progenitors. Human CD34+ cells were isolated from plastic nonadherent mononuclear bone marrow fractions using the 9C5 monoclonal antibody (a gift from Dr Ping Law, Baxter, Inc, Irvine, CA) and immunomagnetic beads (Dynal, Oslo, Norway) as previously described.I4 CD34' cells were plated at a density of IOT cells/mL in transduction medium, which was IMDM with 30% FCS (Gemini Bioproducts), 1% bovine serum albumin (BSA; Sigma), I O (' m o m hydrocortisone, IO-" mol/L 2-mercaptoethanol, 50 U/mL penicillin G + 50 pg/mL streptomycin sulfate (GIBCO), and 2 mmol/ L L-glutamine (GIBCO). Cytokines, when used, were maintained throughout transductions at concentrations of 50 U/mL recombinant human IL-6 (rhIL-6; R&D Systems, Minneapolis, MN), 10 ng/mL rhIL-3 (Immunex Corp. Seattle, WA), and 50 ng/mnL SCF (R&D Systems). CD34' bone marrow progenitor cells were transduced by cell-free supernatant addition or by supernatant addition with allogeneic stromal support, as first described by Moore et al.4 At 24-hour intervals for 3 days, nonadherent cells were collected, pelleted, and resuspended in 5 mL of supernatant from VPF with an equal volume of transduction medium. Protamine sulfate (Lyphomed, Deerfield, IL) was added to a final concentration of 4 pg/mL.
After gene transfer, nonadherent cells were collected by vigorous flushing and plated twice in the same medium for 2-hour periods to permit adherence of stromal cells. Transduced cells were plated in methylcellulose progenitor colony-forming assay, with and without G418 (0.9 mg/mL, screened lots; GIBCO Humcu-specIfic~ CFU crsscry. Marrow cells harvested from each mouse were plated in a human-specific colony-forming assay to determine the number of human hematopoietic progenitor cells engrafted within the murine bone marrow as described."' For clonal analysis. single, well-isolated colonies were plucked from the dish using a micropipette tip. Cells were soaked I hour at room temperature in 1 mL PBS to dissolve the methylcellulose and then divided into two portions. The first portion was pelleted and lysed in 20 pL whole cell lysis buffer and 3 pL proteinase K ( I O mg/mL; GIBCO BRL) for PCR analysis to detect vector sequences. Whole cell lysis buffer is 50 mmol/L KCI, 10 mmoIL Tris-HCI (pH 8.3), 1.5 mmol/L MgCI2. 0. I m@mL gelatin (Sigma). 0.45% NP40, and 0.45% Tween 20. The second portion of each sample was used to generate cytospin slides for immunohistochemical analyses or WrighVGiemsa staining.
Po/yrnrrclsr, clzuin reaction (PCR). For amplification o f LN vector sequences from whole cell lysates, previously described mw primers' were used in I .25 mmol/L Mg'+ PCR buffer (Perkin Elmer Cetus, Norwalk. CT). The initial PCR cycle had a denaturation step of 5 minutes at 94°C followed by an annealing temperature o f 58°C for 2 minutes and an extension step at 72°C for 2 minutes. The subsequent 30 cycles had the same annealing and extension sleph, but denaturation was reduced to I minute at 94°C. G2 vector sequences were amplified from whole cell lysates using previously published primers14 with 0.75 mmol/L Mg". Samples were amplified using the same steps as for neo primers. but with an annealing temperature of 60°C. After amplification by PCR. samples were electrophoresed in 2% agarose gels with ethidium bromide. Gels were photographed with UV illumination and scored as positive only if a product band was easily visible.
Sturi.sticu1 unn1wi.s. All analyses of statistical significance were done using the two-tailed t-test assuming equal variance. Tests were performed by the Excel S.0 statistical function package for Windows (Microsoft Corp, Redmond. WA).
RESULTS
Trunsductio?~ of human colony-forming progenitors with or without stromal support. We examined the effects from CD34' cells from eight adult bone marrow and eight G-CSF-mobilized peripheral blood samples were transduced by supernatant from PA317 cells producing the LN vector (titer = 5 x 106/mL) with or without the support of an irradiated stromal layer. Cells were cultured for 3 days in the presence of the cytokines IL-3, IL-6, and SCF. Addition of vector supernatant was performed on days 1.2, and 3. After transduction, cells were plated in a methylcellulose-based colonyforming assay with and without G418 (0.9 mg/mL, active). Colonies were counted on day 14 and the percentage of transduced progenitors was calculated as G418-resistant CFUhotal CFU (% G41@).
Progenitor 103 the presence of an irradiated allogeneic stromal support layer on retroviral-mediated transduction of CD34+ progenitors from human bone marrow. In this experiment, the cytokines IL-3, IL-6, and SCF were present throughout transduction in all groups. The retroviral vector LN was used for the first set of comparative studies. LN carries the neomycin phosphotransferase, or neo gene, between the LTRs of the Moloney murine leukemia virus. The LN vector confers resistance to the selective agent G418. The efficiency of gene transfer into colony-forming progenitor cells was assessed by the percentage of colonies able to grow in the presence of G418.
In a total of eight transduction experiments without stromal support, 167 G418-resistant colonies were obtained of 2,936 total without G418, averaging 5.7% transduction in liquid suspension (Table 1) . With stromal support, 779 transduced colonies of 2,724 total were obtained, averaging 28.6%. Therefore, the presence of an irradiated stromal layer significantly ( P = .000003) increased the extent of transduction of CD34+ colony-forming progenitors from human bone marrow, in accord with the earlier report by Moore et al. 4 Next, we assessed transduction of G-CSF-mobilized, CD34' peripheral blood progenitors, with or without stromal support. In eight experiments a mean transduction of 30% peripheral blood progenitors was obtained without stromal support (1,235 G418-resistant colonies of 4,100 total), as opposed to 41% with stromal support (1,556/3,835; Table  1 ). In some samples, there was a more marked difference in the extent of transduction with or without stroma, eg, donors P4 and P7, but in the majority of the samples the transduction efficiencies were similar. The difference barely achieved statistical significance ( P = .045). Therefore, although stromal support did slightly increase gene transfer into peripheral blood progenitors, they were transduced more efficiently than bone marrow progenitors without stroma. Table  2 ). The lirsl was supernatant addition with an irradiated stromal support layer (supernatant o n stroma [SOSI), with inclusion 01' the growth factors (GF) IL-3, IL6, and SCF in the transduction media (SOS + GF). The second condition was supernatant addition with a stromal layer, i n the absence of growth factors (SOS ~ GF). The third transduction condition was supernatant addition to a liquid suspension culture (supernatant, no stromal support [SNSI) with the cytokines 11,-3, IL-6, anti SCP. The final condition was supernatant addition to liquid suspension culture i n the absence of cytokines (SNS --GF). The extcnt of transduction was analyzed by G41 X-resistant colony-forming assay. The percentage of G41 %resistant colonics that formed from the progenitors transduced under each condition is shown in Table 2 and
The average transduction extent of G-CSF-mobilized periphernl blood progenitors did no( differ significantly if stroma was present (SOS + GF = 41.2% 5 S. 1 %, SOS ~~ GF = 38.0% + 4.2%'; I' = .4). The extcnt (>l' transduction withou1 stromal support, but in the presencc of cytokines (SNS -t GI?), was 25.8% i 7.0%J. This value was significantly lower than that obtained with stromal support ( P = ,006). Transduction in the absence of both stromal cells and growth factors (SNS -GF) produced significantly lowcr numbers o f G 4 1 X-resistant colonies, with ;n1 average of 13% ( P < : .Ol). Thus, either stromal support or cytokine addition enhanced gene transfer into mobilized pcripheral blood progenitors.
In each o f the live experiments, marrow-derived progcnt o n wcrc also transduced under the same four conditions. A different pattern o f results was obscrved compared with that obtained I'rom transduction of peripheral blood-derived progcnitol-s (Fig I) . As with peripheral blood stem cells, the marrow progenitors were effectively transduced in the presence of an irrndiatctl stromal support layer, with or without the addition o f ' cytokincs (SOS + GF = 27.4%' 2 S.3%, SOS -GF = 24.X%> 2 4.7%). Again, there was no signilicant increase i n the percentage of G41 X-resistant colonies when cytokines were added t o the transductions performed on stroma ( P = .4). The gene transfer extents ol'bonc marrow progenitors in the absence of a stromal support layer were low, with or without cytokine addition (Fig I) . An avet-age oi' 4.2% 2 2.3% human bone marrow-derived progenitors were Iransduccd without growth factors or stromal support (SNS --CiF). The addition of cytokines only increased the transduction cxtent to 7.6% 2 1.5%' (SNS t GF). Therefore, efficient transduction of bone marrow-derived colony-forming progenitors required the presence of bone marrow stromal cells. forming assays measure gene transfer into relatively mature, lineage-committed progenitors. Therefore, transduction of more primitive human cells was studied using the bnx/hu cotransplantation system"' (Fig 2) . After transduction and plating of cells in the 14-day CFU assay, the remaining cells from each experiment were transplanted into immunodeficient mice. Al'ler engraftment periods of 2 to I I Inonths, bone marrow was harvested from the mice and the pcrcentages ctf C45 ' human cells were assessed hy FACS analysis.
To test for the presence o f human progcnitol-a and the extent of vector persistence, human-specific colony-forming assays were pertormed. The plating media contained rhlL-3 and erythropoietin as the only growth factors and allowed the growth o f human, but not murine, progenitors. The cxtent of gene transfer in the recovered cells was assessed by the percentage of colonies ahlc to grow in the selective agent G41 X and by PCK analysis of proviral sequences in individual colonies.
In the first series of in vivo comparison studies, human bone marrow-derived CD34' cells were transduced in vitro by the G2 vector, with or without stromal support, and transplanted into hnx mice. The G2 vector carries between the two LTRs of the Moloney murine leukemia virus a normal cDNA for glucocerebrosidase and is relevant to gene therapy for Gaucher disease.14 After 4 to 6 months of engraftment, bone marrow from the mice was plated in a human-specific CFU assay. The individual human colonies grown in vitro from each mouse were plucked and analyzed by PCR for the presence of provirus. In bnxlhu set no. 1 (Table 3) , six mice that received marrow-derived human progenitors transduced with stromal support generated 54 of 192 (29.5%) human colonies positive by PCR for G2 provirus. In bnxlhu set no. 2 (Table 3) , from 5 mice that received human cells transduced with cytokines, but without stromal support, only 6 of 161 (4.5%) colonies were positive by PCR. Therefore, the average extent of transduction of long-lived human bone marrow progenitors was significantly higher in the presence of cytokines and a stromal support layer than in liquid suspension with cytokines ( P < .00004).
Another series of mice was transplanted with human bone marrow-derived CD34+ progenitors that had been transduced in vitro by the LN vector, with inclusion of the cytokines IL-3, IL-6, and SCF, and with or without stromal support. The mice transplanted with LN-transduced human bone marrow progenitors were divided into two groups based on the time after engraftment when they were studied: 4 to 5 months versus 7 to 11 months posttransplantation. From bnx/hu set 
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Yo Human CD45+ Engraftment   Fig 2. Experimental schema. CD34' progenitors from normal human bone marrow or G-CSF-mobilized peripheral blood were isolated by immunomagnetic selection with greater than 97% purity. Cells were transduced with or without stromal support and cytokines by the addition of cell-free retroviral supernatant at 24-hour intervals for 3 days. The transduction extent of colony-forming progenitors was assessed by CFU assay with or without G418 on day 4. The remainder of the cells from each transduction condition were cotransplanted with IL-%producing stroma into a series of immunedeficient mice. Human progenitors were recovered from the marrow of the mice 2 t o 5 or 7 t o 11 months posttransplantation. The percentage of human CD45' cell engraftment in each mouse was assessed by FACS analysis. Human progenitor cells recovered from each animal were quantitated by human-specific CFU with or without G418. G418-resistant CFU were confirmed t o contain provirus by singlecolony PCR analysis. no. 3 (Table 4) , seven mice that received human CD34' marrow-derived progenitors transduced with stromal support had an average engraftment level of 5.9% 2 1.2% human CD45' cells 4 to 5 months posttransplantation. Human colonies grown from the same mice had an average of 24.0% t: 12.4% G41 8 resistance (Table 4) . Six mice in bnx/hu set no. 4 (Table 4) were transplanted with human progenitors that had been transduced with the LN vector in the absence of stroma. Four to five months posttransplantation, the average engraftment level in set no. 4 was 3.3% t: 1.7% human CD45' cells, and 3.6% 2 2.3% G4 18-resistant human colonies grew from the hnx//zu marrow. The extent of transduction of the human marrow progenitors recovered from set no. 4 was significantly lower than that obtained from the mice in set no. 3 (P = .009). Therefore, stromal support significantly increased the extent of gene transfer into the hematopoietic progenitor cells from human bone marrow that had engrafted the immunodeficient mice for 4 to 5 months. The extent of human cell engraftment was also significantly lower in the mice that had been transplanted with human cells transduced without stromal support as opposed to mice that had received human cells transduced in the presence of stroma (3.3% human CD45' cells v 5.9%; P < .01).
Mice engrafted with LN-transduced human bone marrowderived progenitors for 7 to 11 months were analyzed next. Total: 61169 avg, 3.6 P < .01
CD34' progenitors from human bone marrow were transduced by the LN retroviral vector with or without stromal support and cotransplanted into bnx mice with IL-3-producing stroma. Bone marrow from bnxlhu mice was procured after an engraftment period of 4 to 5 months and assessed by FACS analysis for the extent of human hematopoietic cell engraftment (percentage of human CD45'). Marrow was plated in a human-specific colony-forming assay. Resulting human colonies were counted on day 21 and the percentage of transduced progenitors was calculated. G418-resistant CFU were confirmed to contain provirus by vector-specific PCR.
Abbreviations: ND, not determined; avg, average.
* The transduction of human CD34' cells was performed in the presence (+) or absence (-) of the cytokines IL-3, IL-6, and SCF.
The extents of human cell engraftment and G418 resistance were compared between two sets of mice. Mice in set no. 5 (Table 5 ) had been transplanted with human CD34' marrow progenitors transduced by the LN vector for 3 days in vitro in the presence of cytokines and a stromal layer. Mice in set no. 6 ( Table 5 ) had been transplanted with CD34+ cells from the same marrow donors transduced by the LN vector under the same conditions but lacking the stromal support layer during the 72-hour in vitro transduction period. A profound difference was observed in human CD45+ cell engraftment levels between the two sets of animals. Mice from set no. 5 had levels of human cell engraftment ranging from 1.1 % to 9.9% human CD45' and averaging 4.7% 2.5% (Table 5) . In contrast, mice from set no. 6 had extremely low levels of human cell engraftment, ranging from 0.03% to 2.1% and averaging 0.6% rt 0.7% human CD45+. Few human-specific colonies were grown from the marrow of mice from set no. 6, whereas appreciable numbers of human-specific colonies were recovered from mice from set no. 5 ( Table 5) . Analysis of mice from set no. 5 showed that 23.9% rt 12.8% G418-resistant human colony-forming progenitors had survived 7 to 1 I months of engraftment in the animals. Long-lived, transduced human colony-forming progenitors were recovered infrequently from mice in set no. 6 and averaged 2.4% G418-resistant CFU (Table 5) . We conclude that the absence of stromal support during the 3-day in vitro transduction period had a detrimental effect on gene transfer and viability of very long-lived hematopoietic progenitors from human bone marrow.
Next, the extent of transduction of primitive progenitors from G-CSF-mobilized peripheral blood was analyzed. Human CD34+ cells were transduced in vitro by the vector LN and transplanted into immunodeficient mice. Marrow cells were recovered from the mice after short or long-term engraftment and human-specific colonies were plated in the presence of G418. Again, the mice were analyzed in two groups (2 to 4 months v 7 to 11 months posttransplantation), and the extents of human cell engraftment and G418-resistant long-lived human progenitors were compared.
Mice engrafted for 2 to 4 months were analyzed first (Table 6 ). Set no. 7 had been transplanted with G-CSFmobilized CD34+ progenitors from human peripheral blood transduced by the LN vector for 3 days in vitro in the presence of cytokines and a stromal layer. Mice in set no. 8 had been transplanted with CD34+ cells from the same peripheral blood cell donors transduced under the same conditions but lacking the stromal support layer during the in vitro period. The six mice in bnx/hu set no. 7 (Table 6) had an average engraftment level of 5.3% rt 1.9% human CD45+ cells. Human colonies grown from the same mice had an average of 29.1% ? 10.3% G418 resistance (Table 6 ). Seven mice in bnx/hu set no. 8 (Table 6) had an average engraftment level of 4.1% 2 2.2% human CD45+ cells, and 30.5% rt 13.6% G418-resistant human colonies were recovered. The extent of transduction of the human peripheral blood progenitors recovered from the mice in sets no. 7 and 8 did not differ significantly, nor did the percentages of human cell engraftment. Therefore, stromal support did not significantly CD34+ progenitors from human bone marrow were transduced by the LN retroviral vector with or without stromal support and cotransplanted into bnx mice with IL-3-producing stroma. Bone marrow from bnx/ho mice was procured after an engraftment period of 7 to 11 months and analyzed for the extent of human hematopoietic cell and progenitor content as described.
* The transduction of human CD34' cells was performed in the presence (+l or absence (-1 of the cytokines IL-3, IL-6, and SCF.
increase the extent of gene transfer into the hematopoietic progenitor cells from human blood that had engrafted the immunodeficient mice for 2 to 4 months. Mice that had been engrafted with LN-transduced human peripheral blood progenitors for 7 to 11 months were then analyzed. The extent of human cell engraftment and G418 resistance were compared between two sets of mice. Mice in set no. 9 (Table 7) had been transplanted with human CD34' peripheral blood progenitors transduced by the LN vector for 3 days in vitro in the presence of cytokines and a stromal layer. Mice in set no. 10 (Table 7) had been transplanted with CD34+ cells from the same donors transduced by the LN vector under the same conditions but lacking the stromal support layer during the 72-hour in vitro transduction period. As observed in mice from sets no. 5 and 6, a significant difference was observed in human C D 4 9 cell engraftment levels at 7 to 11 months in mice that had received human progenitors transduced with or without stromal support. Mice from set no. 9 had levels of human cell engraftment ranging from 2.0% to 8.6% human CD45' and averaging 4.2% 2 1.9% ( Table 7) . In contrast, mice from set no. 10 had extremely low levels of human cell engraftment, ranging from 0.01% to 1.0% and averaging 0.3% ? 0.3% human CD45+. Few human-specific colonies were grown from the marrow of mice from set no. 10, in contrast to set no. 9. Only 3 of 1 1 mice from set no. 10 had low, yet detectable numbers of human progenitors after the extended engraftment period (Table 7) . Bone marrow from the mice in set no. 9 grew 21.8% ? 11.2% G418-resistant human colony-forming progenitors that had survived 7 to 11 months of engraftment in the animals, as opposed to 4.5% from set no. 10, which were transduced without stroma. We conclude that the absence of stromal support during the 3-day in vitro transduction period had a detrimental effect on the viability of very long-lived human hematopoietic progenitors from peripheral blood as well as from bone marrow.
DISCUSSION
Transduction conditions that increase the efficiency of gene transfer into primitive hematopoietic cells are needed to augment the efficacy of clinical gene therapy trials. Cellfree retroviral-mediated transduction of human hematopoi-KOHN Human CD34' progenitors from G-CSF-mobilized peripheral blood were transduced by the LN retroviral vector with or without stromal support and cotransplanted into bnx mice with IL-3-producing stroma. Bone marrow from bnx/hu mice was procured after an engraftment period of 2 to 4 months and assessed by FACS analysis and human-specific CFU assay with and without G418 as described.
Abbreviations: PBSC, peripheral blood stem cell; avg, average. *The transduction of human CD34' cells was performed in the presence (+) or absence (-) of the cytokines IL-3, IL-6, and SCF.
etic progenitors is enhanced by bone marrow stromal cell support, as previously rep~rted.~ In the prior study, longterm culture-initiating cells capable of surviving 5 weeks in vitro while retaining clonogenicity were analyzed. We used the b&u immunodeficient mouse cotransplantation model of in vivo human hematopoiesis'' to study transduction of more primitive progenitors. We determined that stromal support enhances transduction and viability of the long-lived progenitors from human bone marrow and peripheral blood.
The necessity for a stromal layer to allow efficient transduction of bone marrow-derived progenitors, which the Belmont group has observed4 and we have confirmed, stands in contrast to reports by Breni et a15 and Cassel et a1,6 who showed efficient transduction of peripheral blood progenitors by cell-free vector in the absence of stroma. By direct comparison, we found that the optimal transduction conditions differ for bone marrow and peripheral blood progenitors. We showed that a stromal underlayer is essential for efficient retroviral-mediated transduction of lineage-restricted, colony-forming progenitors as well as for primitive, long-lived progenitors from human bone marrow. In contrast to bone marrow-derived progenitors, precursors from G-CSF-mobilized peripheral blood were effectively transduced without stromal support if cytokines were present.
The results show that there is a difference between the two cell populations, with the clonogenic progenitors from G-CSF-mobilized peripheral blood, but not bone marrow, being susceptible to transduction without stroma. The disparity may reflect differences in the cell cycle status of the two progenitor populations. The fact that G-CSF-mobilized peripheral blood progenitors are more easily transduced than marrow-derived progenitors may reflect a higher fraction of proliferating committed progenitors. It does not necessarily follow that pluripotent hematopoietic stem cells in peripheral blood are more easily transduced than those in bone marrow. In our study, comparison of the long-lived human progenitors present after 7 to 11 months of engraftment in bnr mice showed that those from bone marrow and those from G-CSF-mobilized peripheral blood actually had similar requirements for successful transduction. With stromal support, 23.9% of long-lived human bone marrow progenitors were transduced compared with 21.8% from peripheral blood, whereas, in the absence of stroma, 2.4% from marrow and 4.5% from peripheral blood contained the Reo gene.
To investigate the requirement for cytokines in transduction of the bone marrow and mobilized peripheral blood progenitor populations, we performed growth factor comparison studies. CD34+ cells from both cell populations were transduced with or without stromal support and with or without addition of the cytokines IL-3, IL-6, and SCF. G-CSFmobilized peripheral blood progenitors were effectively transduced in the presence of either stroma or cytokines and had an unusually high average extent of transduction (13%) without any proliferative stimulus (-stroma, -cytokines). The marrow-derived progenitors were efficiently transduced in the presence of stroma, with or without cytokine addition, but were not transduced to significant extents in the absence of stroma. The presence or absence of cytokines during the transduction had no significant impact on the subsequent engraftment of either total or transduced human cells in bnr mice. The only transduction variable that did have a profound effect was the presence or absence of stromal support. 
P ,0003
Human CD34' progenitors from G-CSF-mobilized peripheral blood were transduced by the LN retroviral vector with or without stromal support and cotransplanted into bnx mice with IL-3-producing stroma. Bone marrow from bnx/hu mice was procured after an engraftment period of 7 to 11 months and assessed by FACS analysis and human-specific CFU assay with and without G418 as described.
Abbreviations: PBSC, peripheral blood stem cell; avg, average.
* The transduction of human CD34' cells was performed in the presence (+) or absence (-) of the cflokines IL-3, IL-6, and SCF.
There may be several mechanisms by which irradiated stromal support layers increase the extent of retroviral-mediated gene transfer into human hematopoietic progenitors. A colocalization effect may exist by which retroviral virions adhere to elements of the stromal extracellular matrix. This effect might facilitate binding and entry of the virions into the hematopoietic cells attached to fibronectin or other adhesion molecules on the stromal surface. Moritz et a l l 5 recently showed that flasks coated with the CS-l cell adhesion domain of fibronectin increased the extent of gene transfer into hematopoietic progenitor cells as efficiently as viable stromal cell support. A second mechanism by which stromal cells might enhance the extent of gene transfer into hematopoietic progenitors is through direct stimulation by attachment. Integrins can transmit activation signals via tyrosine phosphorylation and cytoplasmic alkalinization in response to attachment of various cell types to extracellular matrix molecules. '6 It is possible that hematopoietic progenitors are similarly stimulated by adhesion to extracellular matrix proteins. This activation, in conjunction with signals from stromal-derived or exogenous cytokines, might be sufficient to bring quiescent marrow progenitors into cell cycle or to upregulate expression of the amphotropic receptor. A third mode of enhanced transduction by stromal support may be production of cytokines required to increase cycling of quiescent hematopoietic progenitors, allowing retroviral integration. Candidate stromal-derived cytokines are membrane-bound SCF,I7 leukemia-inhibitory factor (LIF),'* macrophage inhibitory protein-la (MIF"la),'9.20 and the recently cloned fIk-2 ligand,2'*22 which have all been shown to stimulate division of primitive hematopoietic cells.
Because the extent of retroviral integration correlates with the percentage of cycling cells,' the stromal-mediated increase in transduction of marrow progenitors that Moore et a14 initially observed and we have confirmed appears to conflict with previous reports that implicate stromal cells as negative regulators of hematopoie~is.~~.~~ However, in our system, macrophages comprise less than 1% of the adherent layer, as shown by in situ immunohistochemical staining, and 100% of the transduction media is replaced at 24-hour intervals. Therefore, molecules such as transforming growth factor-,B may not accumulate to inhibitory levels before the subsequent media change.
In the single clinical trial of gene transfer into bone mar-row reported to date, relatively efficient marking of stem cells has been achieved with a minimalist approach in which the marrow is exposed to vector supernatant once, without stroma or c y t o k i n e~.~~ T h e relative success may reflect the fact that the marrow was obtained from patients rebounding after high-dose chemotherapy and may have contained a high fraction of spontaneously proliferating stem cells. Our data indicate that effective transduction of progenitors from normal marrow requires the support of a stromal layer. The use of stromal support during the in vitro transduction period eliminates the need for addition of recombinant cytokines, which may be difficult to obtain for clinical trials.
